WallStSmart

BHP Group Limited (BHP)vsBristol-Myers Squibb Company (BMY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BHP Group Limited generates 11% more annual revenue ($53.99B vs $48.48B). BHP leads profitability with a 19.0% profit margin vs 15.0%. BHP appears more attractively valued with a PEG of 5.95. BHP earns a higher WallStSmart Score of 65/100 (C+).

BHP

Buy

65

out of 100

Grade: C+

Growth: 5.3Profit: 8.5Value: 3.3Quality: 5.0

BMY

Buy

60

out of 100

Grade: C+

Growth: 4.7Profit: 9.0Value: 6.7Quality: 4.5
Piotroski: 6/9Altman Z: 1.42
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BHPSignificantly Overvalued (-83.1%)

Margin of Safety

-83.1%

Fair Value

$43.51

Current Price

$84.72

$41.21 premium

UndervaluedFair: $43.51Overvalued
BMYUndervalued (+32.0%)

Margin of Safety

+32.0%

Fair Value

$88.08

Current Price

$56.16

$31.92 discount

UndervaluedFair: $88.08Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BHP5 strengths · Avg: 9.0/10
Market CapQuality
$214.23B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
40.7%10/10

Strong operational efficiency at 40.7%

Return on EquityProfitability
24.7%9/10

Every $100 of equity generates 25 in profit

EPS GrowthGrowth
27.5%8/10

Earnings expanding 27.5% YoY

Free Cash FlowQuality
$4.31B8/10

Generating 4.3B in free cash flow

BMY4 strengths · Avg: 9.3/10
Return on EquityProfitability
38.7%10/10

Every $100 of equity generates 39 in profit

Operating MarginProfitability
33.0%10/10

Strong operational efficiency at 33.0%

Market CapQuality
$114.68B9/10

Large-cap with strong market position

P/E RatioValuation
15.7x8/10

Attractively priced relative to earnings

Areas to Watch

BHP1 concerns · Avg: 2.0/10
PEG RatioValuation
5.952/10

Expensive relative to growth rate

BMY4 concerns · Avg: 2.3/10
Revenue GrowthGrowth
2.6%4/10

2.6% revenue growth

PEG RatioValuation
181.372/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.422/10

Distress zone — elevated risk

Debt/EquityHealth
2.551/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : BHP

The strongest argument for BHP centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 19.0% and operating margin at 40.7%. Revenue growth of 10.8% demonstrates continued momentum.

Bull Case : BMY

The strongest argument for BMY centers on Return on Equity, Operating Margin, Market Cap.

Bear Case : BHP

The primary concerns for BHP are PEG Ratio.

Bear Case : BMY

The primary concerns for BMY are Revenue Growth, PEG Ratio, Altman Z-Score. Debt-to-equity of 2.55 is elevated, increasing financial risk.

Key Dynamics to Monitor

BHP profiles as a mature stock while BMY is a value play — different risk/reward profiles.

BHP carries more volatility with a beta of 0.80 — expect wider price swings.

BHP is growing revenue faster at 10.8% — sustainability is the question.

BHP generates stronger free cash flow (4.3B), providing more financial flexibility.

Bottom Line

BHP scores higher overall (65/100 vs 60/100), backed by strong 19.0% margins and 10.8% revenue growth. BMY offers better value entry with a 32.0% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BHP Group Limited

BASIC MATERIALS · OTHER INDUSTRIAL METALS & MINING · USA

BHP Group engages in the natural resources business in Australia, Europe, China, Japan, India, South Korea, the rest of Asia, North America, South America and internationally. The company is headquartered in Melbourne, Australia.

Bristol-Myers Squibb Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.

Visit Website →

Want to dig deeper into these stocks?